Digi-HTA assessment scale updated in Finland

The Digi-HTA framework is managed by the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA). Its main aim is to evaluate digital health technologies by assessing clinical, technical, economic, usability, interoperability, and cybersecurity aspects, thereby supporting evidence-based decision-making for their adoption within the healthcare system.

In April 2026, the FinCCHTA updated the Digi-HTA assessment scale. The assessment uses a traffic light model based on scores assigned across five subareas: impact, safety, costs, data security and data protection, and usability and accessibility. For each subarea, a product may now receive a score of 2, 1.7, 0.9, or -4. FinCCHTA determines the final evaluation level based on the product’s total score. The maximum possible score is 10 points. 

The recommendation categories are defined as follows:

• Total score = 10: product meets the evaluation criteria (green category);
• 9 ≤ Total score < 10: product mainly meets the evaluation criteria (light green category);
• 7 ≤ Total score < 9: product partially meets the evaluation criteria (yellow category);
• 4 ≤ Total score < 7: product meets the evaluation criteria to a limited extent (orange category);
• Total score ≤ 4: carefully consider before adopting the product. 

In addition, if any individual subarea receives a score of -4, the overall rating is automatically assigned to the red category, meaning that the product should be carefully considered before use.

Digi-HTA assessments are based on information provided by the company, supplemented by a literature review, expert assessments, and any additional questions to the company. Information about the product is collected using the Digi-HTA questionnaire and the self-assessment form developed in the National Emergency Supply Agency's Cyber Health Project. 

The evaluation is valid for three years. A company may request reassessment of an individual subarea if significant improvements have been made to the product or if new, substantial evidence on the product’s effectiveness becomes available.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.